文献速递神经肿瘤

髓系细胞触发受体2(TREM2)调控胶质母细胞瘤的吞噬作用

Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma.
PubMed 文献 · Neuro Oncol · 2024-01-01

研究利用单细胞RNA测序和流式细胞术分析人胶质瘤髓系亚群中TREM2的表达,并在两种小鼠胶质瘤模型中探究Trem2对肿瘤进展和髓系细胞免疫调节的作用,发现TREM2表达与免疫抑制通路无关,而与经典吞噬标志物LYZ和CD163正相关;Trem2+髓系细胞较Trem2-细胞肿瘤摄取增强,TREM2通过Syk信号介导吞噬。

要点

  • TREM2表达与免疫抑制通路无关,而与吞噬标志物LYZ和CD163正相关。
  • Trem2缺陷对胶质瘤发生非必需,但Trem2+髓系细胞较Trem2-细胞肿瘤摄取增强。
  • TREM2通过Syk信号介导吞噬,可能作为脑肿瘤的潜在治疗策略。

核心结论

  • TREM2在胶质瘤中与免疫抑制无关,而是吞噬作用的重要调节因子,可能被开发为脑肿瘤的潜在治疗策略。

研究设计与样本

  • 采用反向转化研究,利用单细胞RNA测序和流式细胞术表征人胶质瘤髓系亚群中TREM2的表达。
  • 使用两种不同的小鼠胶质瘤模型研究Trem2对肿瘤进展和髓系细胞免疫调节的作用。
  • 设计体内追踪胶质瘤细胞吞噬的方法,并采用体外实验理解TREM2信号对肿瘤摄取的影响。

主要发现

  • TREM2表达与免疫抑制通路不相关,而与经典吞噬标志物溶菌酶(LYZ)和巨噬细胞清道夫受体(CD163)呈强正相关。
  • Trem2缺陷对胶质瘤发生非必需,但Trem2+髓系细胞较Trem2-细胞显示增强的肿瘤摄取。
  • TREM2通过Syk信号介导吞噬作用。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastomas (GBMs) are central nervous system tumors that resist standard-of-care interventions and even immune checkpoint blockade. Myeloid cells in the tumor microenvironment can contribute to GBM progression; therefore, emerging immunotherapeutic approaches include reprogramming these cells to achieve desirable antitumor activity. Triggering receptor expressed on myeloid cells 2 (TREM2) is a myeloid signaling regulator that has been implicated in a variety of cancers and neurological diseases with contrasting functions, but its role in GBM immunopathology and progression is still under investigation. METHODS: Our reverse translational investigations leveraged single-cell RNA sequencing and cytometry of human gliomas to characterize TREM2 expression across myeloid subpopulations. Using 2 distinct murine glioma models, we examined the role of Trem2 on tumor progression and immune modulation of myeloid cells. Furthermore, we designed a method of tracking phagocytosis of glioma cells in vivo and employed in vitro assays to mechanistically understand the influence of TREM2 signaling on tumor uptake. RESULTS: We discovered that TREM2 expression does not correlate with immunosuppressive pathways, but rather showed strong a positive association with the canonical phagocytosis markers lysozyme (LYZ) and macrophage scavenger receptor (CD163) in gliomas. While Trem2 deficiency was found to be dispensable for gliomagenesis, Trem2+ myeloid cells display enhanced tumor uptake compared to Trem2- cells. Mechanistically, we demonstrate that TREM2 mediates phagocytosis via Syk signaling. CONCLUSIONS: These results indicate that TREM2 is not associated with immunosuppression in gliomas. Instead, TREM2 is an important regulator of phagocytosis that may be exploited as a potential therapeutic strategy for brain tumors.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Peshoff MM, Gupta P, Oberai S, et al. Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma. Neuro Oncol. 2024. PMID: 38237157. doi:10.1093/neuonc/noad257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。